Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
  • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
  • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/16—Amides, e.g. hydroxamic acids
  • A61K31/18—Sulfonamides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/4245—Oxadiazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P5/00—Drugs for disorders of the endocrine system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
  • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
  • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
  • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
  • C07D471/10—Spiro-condensed systems

Definitions

• the present invention relates to 1,3,4-oxadiazole sulfamide derivative compounds having histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof, or pharmaceutically acceptable salts thereof; uses thereof for the preparation of therapeutic medicaments; methods of treating diseases using the same; pharmaceutical compositions comprising the same; and methods for preparing the same.
• HDAC6 histone deacetylase 6
• Post-translational modifications such as acetylation are very crucial regulatory modules at the heart of biological processes in the cells and are tightly regulated by a multitude of enzymes. Histones are the chief protein components of chromatin and act as spools around which DNA strands. Also, the balance of histone acetylation and deacetylation is a critical role in the regulation of gene expression.
• Histone deacetylases are enzymes that remove acetyl groups from lysine residues on histone proteins of chromatin, and are known to be associated with gene silencing and induce cell cycle arrest, angiogenic inhibition, immune regulation, cell death, etc. (Hassig et al., Curr. Opin. Chem. Biol. 1997, 1, 300-308). In addition, it was reported that the inhibition of enzymatic function of HDACs induces the apoptosis of cancer cells in vivo by reducing the activity of cancer cell survival-associated factors and activating cancer cell apoptosis-associated factors (Warrell et al, J. Natl. Cancer Inst. 1998, 90, 1621-1625).
• HDACs In humans, 18 HDACs have been identified and are subdivided into four classes based on their homology to yeast HDACs. Among them, 11 HDACs use zinc as a cofactor and can be divided into three groups: Class I (HDAC1, 2, 3 and 8), Class II (IIa: HDAC4, 5, 7 and 9; IIb: HDAC6 and 10), Class IV (HDAC 11). Additionally, 7 HDACs of Class III (SIRT 1-7) require NAD + instead of zinc as a cofactor (Bolden et al., Nat. Rev. Drug Discov. 2006, 5(9), 769-784).
• HDAC inhibitors are in preclinical or clinical development, but to date, only non-selective HDAC inhibitors have been identified as anticancer agents, and only vorinostat (SAHA) and romidepsin (FK228) have been approved for the treatment of cutaneous T-cell lymphoma.
• SAHA vorinostat
• FK2228 romidepsin
• non-selective HDAC inhibitors are known to cause side effects such as fatigue and nausea, generally at high doses (Piekarz et al., Pharmaceuticals 2010, 3, 2751-2767). Such side effects have been reported to be due to the inhibition of class I HDACs. Due to such side effects, the use of non-selective HDAC inhibitors in the development of drugs other than anticancer drugs has been limited (Witt et al., Cancer Letters, 2009, 277, 8-21).
• selective HDAC inhibitors have potential to be developed as therapeutic agents effective for the treatment of various diseases (Matthias et al., Mol. Cell. Biol. 2008, 28, 1688-1701).
• HDAC6 a member of Class IIb HDACs, is present mainly in the cytoplasm and is involved in the deacetylation of a number of non-histone substrates (HSP90, cortactin, etc.), including tubulin, (Yao et al., Mol. Cell 2005, 18, 601-607). HDAC6 has two catalytic domains, and the zinc finger domain of C-terminal can bind to ubiquitinated proteins.
• HDAC6 has a number of non-histone proteins as substrates, and thus plays an important role in various diseases, including cancer, inflammatory diseases, autoimmune diseases, neurological diseases and neurodegenerative disorders (Santo et al., Blood 2012 119: 2579-258; Vishwakarma et al., International Immunopharmacology 2013, 16, 72-78; Hu et al., J. Neurol. Sci. 2011, 304, 1-8).
• the common structural characteristic of various HDAC inhibitors is a structure consisting of a cap group, a linker and a zinc-binding group (ZBG), as shown in the following Vorinostat structure.
• ZBG zinc-binding group
• Many researchers have conducted studies on enzyme inhibitory activity and selectivity by structurally modifying the cap group and the linker.
• the zinc-binding group is known to play a more important role in enzyme inhibitory activity and selectivity (Wiest et al., J. Org. Chem. 2013 78: 5051-5065; Methot et al., Bioorg. Med. Chem. Lett. 2008, 18, 973-978).
• the zinc-binding group is generally a hydroxamic acid or benzamide derivative.
• the hydroxamic acid derivative exhibits a potent HDAC inhibitory effect, but has problems of low bioavailability and severe off-target activity.
• the benzamide derivative has a problem in that it can produce toxic metabolites in vivo , because it contains aniline (Woster et al., Med. Chem. Commun. 2015, online publication).
• Another object of the present invention is to provide pharmaceutical compositions containing 1,3,4-oxadiazole sulfamide derivative compounds having selective HDAC6 inhibitory activity, stereoisomers thereof, or pharmaceutically acceptable salts thereof.
• Still another object of the present invention is to provide methods for preparing the novel compounds.
• Still another object of the present invention is to provide pharmaceutical compositions for prevention or treatment of HDAC6 activity-associated diseases, including infectious diseases; neoplasms; endocrine, nutritional and metabolic diseases; mental and behavioral disorders; neurological diseases; diseases of the eye and adnexa; cardiovascular diseases; respiratory diseases; digestive diseases; diseases of the skin and subcutaneous tissue; diseases of the musculoskeletal system and connective tissue; or congenital malformations, deformations and chromosomal abnormalities, which contain the above compound.
• infectious diseases including infectious diseases; neoplasms; endocrine, nutritional and metabolic diseases; mental and behavioral disorders; neurological diseases; diseases of the eye and adnexa; cardiovascular diseases; respiratory diseases; digestive diseases; diseases of the skin and subcutaneous tissue; diseases of the musculoskeletal system and connective tissue; or congenital malformations, deformations and chromosomal abnormalities, which contain the above compound.
• Still another object of the present invention is to provide the use of the compounds for the preparation of therapeutic medicaments against HDAC6 activity-associated diseases.
• Yet another object of the present invention is to provide methods for treating HDAC6 activity-associated diseases, which comprise administering a therapeutically effective amount of the pharmaceutical compositions containing the compounds.
• the present inventors have discovered 1,3,4-oxadiazole sulfamide derivative compounds, which have histone deacetylase 6 (HDAC6) inhibitory activity, and have found that these compounds can be used for the inhibition or treatment of histone deacetylase 6 (HDAC6) activity-associated diseases, thereby completing the present invention.
• HDAC6 histone deacetylase 6
• the present invention provides an 1,3,4-oxadiazole sulfamide derivative compound represented by the following formula I, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof:
• L 1 , L 2 or L 3 are each independently -(C 0 -C 2 alkl)-;
• Z 1 to Z 4 are each independently N or CR Z , wherein R Z is -H or -X;
• R 1 is -CX 2 H or -CX 3 ;
• R 2 is , , or -NR 8 R 9 ,
• a to d are each independently an integer of 1, 2 or 3,
• Ra to Rd are each independently -H or -(C 1 -C 4 alkyl),
• the dotted line is a single bond or a double bond
• R 4 and R 5 are each independently -H, -X, -(C 1 -C 4 alkyl), aryl or -NReRf, provided that the dotted line is a double bond, R 5 is null,
• Re and Rf are each independently -H or -(C 1 -C 4 alkyl),
• R 11 and R 12 are each independently -H or -(C 1 -C 4 alkyl),
• R 1 , L 1 , Z 1 , Z 2 , Z 3 and Z 4 are as defined above;
• X is F, Cl, Br or I.
• L 1 or L 3 are each independently -(C 0 alkyl)-;
• L 2 is -(C 1 alkyl)-
• Z 1 to Z 4 are each independently N or CR Z , wherein R Z is -H or -X;
• R 1 is -CX 2 H or -CX 3 ;
• R 2 is , or -NR 8 R 9 ,
• a to d are each independently an integer of 1 or 2
• Ra to Rd are each independently -H or -(C 1 -C 4 alkyl),
• R 3 is -aryl or -heteroaryl, wherein at least one H of the -aryl or -heteroaryl may be substituted with -X;
• X is F, Cl, Br or I.
• L 1 or L 3 are each independently -(C 0 alkyl)-;
• L 2 is -(C 1 alkyl)-
• Z 1 to Z 4 are each independently N or CR Z , wherein R Z is -H or -X;
• R 1 is -CF 2 H or -CF 3 ;
• R 2 is or ,
• a to d are each independently an integer of 1 or 2
• Ra to Rd are each independently -H or -(C 1 -C 4 alkyl),
• R 3 is -aryl or -heteroaryl, wherein at least one H of the -aryl or -heteroaryl may be substituted with -X;
• X is F, Cl, Br or I.
• L 1 or L 3 are each independently -(C 0 alkyl)-;
• L 2 is -(C 1 alkyl)-
• Z 1 to Z 4 are each independently N or CR Z , wherein R Z is -H or -X;
• R 1 is -CF 2 H or -CF 3 ;
• R 2 is or ,
• a and b are 2, c and d are 1,
• Ra to Rd are each independently -H or -(C 1 -C 4 alkyl),
• R 3 is -aryl or -heteroaryl, wherein at least one H of the -aryl or -heteroaryl may be substituted with -F;
• X is F or Cl.
• the compounds represented by formula I, stereoisomers thereof or pharmaceutically acceptable salts thereof may be selected from the group consisting of compounds 11301, 11302, 11303, 11305, 11306, 11307, 11308, 11313, 11314, 11315, 11316, 11318, 11321, 11363, 11379, 11440, 11498, 11574, 11575, 11641, 11653, 11654, 11659, 11662, 11670, 11671, 11672, 11823, 11824, 11825, 11826, 11827, 11828, 11829, 11830, 11831, 11832 and 11833.
• the compounds represented by formula I, stereoisomers thereof or pharmaceutically acceptable salts thereof may be selected from the group consisting of compounds 11301, 11302, 11303, 11305, 11306, 11313, 11314, 11315, 11316, 11363, 11379, 11440, 11498, 11574, 11641, 11654, 11659, 11670, 11671, 11672, 11825, 11829, 11830, 11831 and 11832.
• the term "pharmaceutically acceptable salt” means any salt that is generally used in the pharmaceutical field.
• the pharmaceutically acceptable salt include, but are not limited to, salts with inorganic ions such as calcium, potassium, sodium or magnesium ions, salts with inorganic acids such as hydrochloric acid, nitric acid, phosphoric acid, bromic acid, iodic acid, perchloric acid or sulfuric acid, salts with organic acids such as acetic acid, trifluoroacetic acid, citric acid, maleic acid, succinic acid, oxalic acid, benzoic acid, tartaric acid, fumaric acid, mandelic acid, propionic acid, lactic acid, glycolic acid, gluconic acid, galacturonic acid, glutamic acid, glutaric acid, glucuronic acid, aspartic acid, ascorbic acid, carbonic acid, vanillic acid, hydroiodic acid or the like, salts with sulfonic acids such as methanesulfonic
• preferred salts include salts with hydrochloric acid, phosphoric acid, sulfuric acid, trifluoroacetic acid, citric acid, bromic acid, maleic acid, tartaric acid or the like, and preferred examples of such compounds include compounds 11293, 11301, 11306, 11309, 11313, 11317, 11321 and 11787 as disclosed herein.
• the compounds represented by formula I may contain one or more asymmetrical carbon atoms, and thus may exist in the form of racemates, racemic mixtures, single enantiomers, diastereomeric mixtures, and individual diastereomers.
• the compounds of formula I can be separated into such isomers by methods known in the art, for example, column chromatography or HPLC.
• stereoisomers of the compounds of formula I may be synthesized by stereospecific synthesis using optically pure starting materials and/or reagents of known configuration.
• the present invention provides methods for the preparation of the 1,3,4-oxadiazole sulfamide derivative compounds presented by formula I, streoisomers thereof, or pharmaceutically acceptable salts thereof.
• Reaction scheme 1 above shows a general method for synthesis of compounds having a sulfamide structure [Journal of Organic Chemistry, 2003, vol. 68, 115-119].
• a methyl group is introduced into 1,1'-sulfonyldiimidazole to increase reactivity, followed by substitution with an amine. This process is carried out twice, thereby preparing a compound of formula 3-1-5.
• an alkyl group is introduced into the compound of formula 3-1-5 in the presence of sodium hydride, and the ester moiety is substituted with hydrazine, thereby preparing a compound of formula 3-1-7.
• the compound of formula 3-1-7 is reacted with trifluoroacetic anhydride or difluoroacetic anhydride to synthesize a compound of formula 3-1-9 or formula 3-1-8, which is then reacted with 1-methoxy-N-triethylamminiosulfonyl-methaneimidate (Burgess reagent), thereby synthesizing compounds 11198 , 11199 , 11440 and 11498 , which have an oxadiazole structure.
• Reaction scheme 2 above shows a process of introducing a substituent into a secondary amine. As shown therein, a protecting group is removed from the compound of formula 3-1-9 synthesized according to reaction scheme 1, thereby synthesizing compounds 11293, 11301, 11309, 11313, 11317 and 11321 .
• a substituent is introduced into the compound of formula 3-2-1 by reaction with acyl chloride or sulfonyl chloride, or an alkyl group is introduced into the compound of formula 3-2-1 by reductive amination, thereby synthesizing compounds 11294, 11295, 11296, 11297, 11298, 11299, 11300, 11302, 11303, 11304, 11305, 11306, 11307, 11308, 11310, 11311, 11312, 11314, 11315, 11316, 11318, 11319, 11320 and 11322 .
• Reaction scheme 3 above shows another process of introducing a substituent into secondary amine.
• the protecting group of the compound of formula 3-1-6 synthesized according to reaction scheme 1 is removed to synthesize a compound of formula 3-3-1, and an alkyl group is introduced into the compound of formula 3-3-1 by reductive amination, thereby synthesizing a compound of formula 3-3-2.
• Reaction scheme 4 above shows a reaction for synthesizing a compound which is to be substituted into a sulfamide structure. As shown therein, a protecting group is introduced into a secondary amine which is then reacted with methanesulfonyl chloride to prepare a compound of formula 3-4-3.
• Reaction scheme 5 above shows a general method for synthesizing compounds having a sulfamide structure.
• a compound of formula 3-5-1 is reacted with a compound of formula 3-5-2 to prepare a compound of formula 3-5-3, and chlorosulfonyl isocyanate and tert-butanol are reacted with each other, and then reacted with the compound of formula 3-5-3, thereby preparing a compound of formula 3-5-4.
• a methyl group is introduced into the secondary amine to prepare a compound of formula 3-5-5, which is then deprotected, thereby preparing a compound of formula 3-5-6.
• the compound of formula 3-5-6 is subjected to a substitution reaction with the compound of formula 3-4-3 prepared according to reaction scheme 4, thereby preparing a compound of formula 3-5-7.
• the compound of formula 3-5-7 is deprotected, thereby preparing a compound of formula 3-5-8.
• the compound of formula 3-5-8 is subjected to a substitution reaction or a reductive amination reaction to prepare a compound of formula 3-5-9, which is then reacted with hydrazine to prepare a compound of formula 3-5-10.
• the compound of formula 3-5-10 is reacted with trifluoroacetic anhydride or difluoroacetic anhydride to thereby prepare a compound of formula 3-5-11 which has an oxadiazole structure.
• Reaction scheme 6 above shows a process of introducing a substituent into a secondary amine.
• the compound of formula 3-1-6 synthesized according to reaction scheme 1 is reacted with hydrazine to synthesize a compound of formula 3-6-1.
• the compound of formula 3-6-1 is reacted with trifluoroacetic anhydride or difluoroacetic anhydride to prepare a compound of formula 3-6-2 having an oxadiazole structure.
• the compound of formula 3-6-2 is deprotected, thereby synthesizing compound 11787 .
• An alkyl group is introduced into compound 11787 or the compound of formula 3-6-3 by reductive amination, thereby synthesizing compounds 11788 and 11789 .
• compositions comprising 1,3,4- oxadiazole sulfamide derivative compounds, the use thereof and the method of treating diseases
• the present invention provides a pharmaceutical composition for preventing or treating histone deacetylase 6 (HDAC6) activity-associated diseases, which contains, as an active ingredient, a compound represented by the following formula I, a stereoisomer thereof or a pharmaceutically acceptable salt thereof:
• HDAC6 histone deacetylase 6
• the pharmaceutical composition according to the present invention exhibits a remarkable effect on the prevention or treatment of histone deacetylase 6 (HDAC6) activity-associated diseases by selectively inhibiting histone deacetylase 6 (HDAC6).
• HDAC6 histone deacetylase 6
• the histone deacetylase 6 (HDAC6) activity-associated diseases include infectious diseases such as prion disease; neoplasms such as benign tumor(e.g. myelodysplastic syndrome) or malignant tumor(e.g. multiple myeloma, lymphoma, leukemia, lung cancer, rectal cancer, colon cancer, prostate cancer, urothelial carcinoma, breast cancer, melanoma, skin cancer, liver cancer, brain cancer, gastric cancer, ovarian cancer, pancreatic cancer, head and neck cancer, oral cancer, or glioma); endocrine, nutritional and metabolic diseases such as Wilson's disease, amyloidosis or diabetes; mental and behavioral disorders such as depression or Rett's syndrome, and the like; neurological diseases such as atrophy of central nervous system (e.g.
• Huntington's disease spinal muscular atrophy (SMA), spinocerebellar ataxia (SCA)), neurodegenerative disease (e.g. Alzheimer's disease), movement disorder (e.g. Parkinson's disease), neuropathy (e.g. hereditary neuropathy (Charcot-Marie-Tooth disease), sporadic neuropathy, inflammatory neuropathy, drug-induced neuropathy), motor neuron diseases (amyotrophic lateral sclerosis (ALS)), or demyelinating diseases of the central nervous system (e.g.
• MS multiple sclerosis
• diseases of the eye and adnexa such as uveitis
• cardiovascular diseases such as atrial fibrillation or stroke and the like
• respiratory diseases such as asthma
• digestive diseases such as alcoholic liver disease, inflammatory bowel disease, Crohn's disease or ulcerative bowel disease, and the like
• diseases of the skin and subcutaneous tissue such as psoriasis
• diseases of the musculoskeletal system and connective tissue such as rheumatoid arthritis, osteoarthritis or systemic lupus erythematosus (SLE), and the like
• congenital malformations, deformations and chromosomal abnormalities such as autosomal dominant polycystic kidney disease, as well as disorders or diseases associated with the abnormal function of histone deacetylase.
• the pharmaceutically acceptable salt is as described above with respect to a pharmaceutically acceptable salt of the compound represented by formula I according to the present invention.
• the pharmaceutical composition according to the present invention may further contain at least one pharmaceutically acceptable carrier in addition to the compound of formula I, an isomer thereof or a pharmaceutically acceptable salt thereof.
• the pharmaceutically acceptable carrier that is used in the present invention may be at least one of physiological saline, sterile water, Ringer solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol, and a mixture of two or more thereof. If necessary, the composition may contain other conventional additives such as an antioxidant, a buffer or a bacteriostatic agent.
• compositions can be formulated into injectable formulations such as solutions, suspensions, turbid fluid, etc, pills, capsules, granules or tablets using a diluent, a dispersing agent, a surfactant, a binder and a lubricant.
• injectable formulations such as solutions, suspensions, turbid fluid, etc, pills, capsules, granules or tablets using a diluent, a dispersing agent, a surfactant, a binder and a lubricant.
• the composition of the present invention may be in the form of patches, liquids, pills, capsules, granules, tablets, suppositories, etc.
• These formulations can be prepared either by conventional methods that are used for formulation in the art or by the method disclosed in Remington's Pharmaceutical Science (the latest edition), Mack Publishing Company, Easton PA.
• the pharmaceutical composition of the present invention may be administered orally or parenterally (e.g., intravenously, subcutaneously, intraperitoneally or topically) depending on the intended use.
• the dose of the pharmaceutical composition varies depending on the patient's weight, age, sex, health conditions and diet, the time of administration, the mode of administration, excretion rate, the severity of the disease, and the like.
• the daily dose of the compound of formula I according to the present invention may be about 1 to 1000 mg/kg, preferably 5 to 100 mg/kg, and may be administered once to several times a day.
• the pharmaceutical composition of the present invention may further contain, in addition to the compound represented by formula I, a stereoisomer thereof or a pharmaceutically acceptable salt thereof, one or more active ingredients that exhibit medicinal efficacy identical or similar thereto.
• the present invention also provides a method for preventing or treating a histone deacetylase-mediated disease, which comprises administering a therapeutically effective amount of the compound represented by formula I, a stereoisomer thereof or a pharmaceutically acceptable salt thereof.
• terapéuticaally effective amount refers to the amount of the compound represented by formula I, which is effective for the prevention or treatment of histone deacetylase 6 activity-associated diseases.
• the present invention also provides a method of selectively inhibiting HDAC6, which comprises administering the compound of formula I, a stereoisomer thereof or a pharmaceutically acceptable salt thereof to mammals including humans.
• the method of preventing or treating histone deacetylase 6 activity-associated disease includes inhibiting or averting the disease as well as addressing the disease itself, prior to the onset of symptoms by administering the compound represented by formula I.
• the magnitude of a prophylactic or therapeutic dose of a particular active ingredient will vary with the nature and severity of the disease or condition, and may also vary according to the route by which the active ingredient is administered.
• the dose and the dose frequency will also vary according to the age, body weight, and response of the individual patient. Suitable dosing regimens can be readily selected by those skilled in the art with due consideration of such factors.
• the method of preventing or treating histone deacetylase 6 activity-associated disease may further comprise administering a therapeutically effective amount of an additional active agent helpful for the treatment of the disease together with the compound represented by formula I, in which the additional active agent can exhibit a synergistic effect with the compound of formula I or an assistant effect.
• the present invention is also intended to provide the use of the compound represented by formula I, a stereoisomer thereof or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for treating histone deacetylase 6 activity-associated disease.
• the compound represented by formula I may be mixed with a pharmaceutically acceptable adjuvant, diluent, carrier or the like, and combined with other active agents such that the active ingredients can have synergistic effects.
• composition and treatment method of the present invention may be appropriately combined unless contradictory to one another.
• the compounds represented by formula I, stereoisomers thereof or pharmaceutically acceptable salts thereof can selectively inhibit HDAC6, and thus exhibit excellent effects on the prevention or treatment of histone deacetylase 6 activity-associated diseases.
• Example 1 Compound 11198, N-(4-fluorophenyl)-N-(4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)morpholine-4-sulfonamide
• Example 2 Compound 11199, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(4-fluorophenyl)morpholine-4-sulfonamide
• Example 3 Compound 11293, N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylpiperazine-1-sulfonamide hydrochloride
• Example 4 Compound 11294, 4-acetyl-N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylpiperazine-1-sulfonamide
• Example 5 Compound 11295, N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenyl-4-propionylpiperazine-1-sulfonamide
• Example 6 Compound 11296, N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-4-isobutyryl-N-phenylpiperazine-1-sulfonamide
• Example 7 Compound 11297, N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-4-(methylsulfonyl)-N-phenylpiperazine-1-sulfonamide
• Example 8 Compound 11298, N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-4-methyl-N-phenylpiperazine-1-sulfonamide
• Example 9 Compound 11299, 4-ethyl-N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylpiperazine-1-sulfonamide
• Example 10 Compound 11300, N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-4-isopropyl-N-phenylpiperazine-1-sulfonamide
• Example 11 Compound 11301, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-phenylpiperazine-1-sulfonamide hydrochloride
• Example 12 Compound 11302, 4-acetyl-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-phenylpiperazine-1-sulfonamide
• Example 13 Compound 11303, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-phenyl-4-propionylpiperazine-1-sulfonamide
• Example 14 Compound 11304, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-4-isobutyryl-N-phenylpiperazine-1-sulfonamide
• Example 15 Compound 11305, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-4-(methylsulfonyl)-N-phenylpiperazine-1-sulfonamide
• Example 16 Compound 11306 hydrochloride , N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-4-methyl-N-phenylpiperazine-1-sulfonamide hydrochloride
• Example 17 Compound 11307, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-4-ethyl-N-phenylpiperazine-1-sulfonamide
• Example 18 Compound 11308, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-4-isopropyl-N-phenylpiperazine-1-sulfonamide
• Example 19 Compound 11309, N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(3-fluorophenyl)piperazine-1-sulfonamide hydrochloride
• reaction mixture was cooled down to the room temperature to terminate the reaction. Then, saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO 4 , filtered, and concentrated in vacuo.
• Example 20 Compound 11310, N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(3-fluorophenyl)-4-(methylsulfonyl)piperazine-1-sulfonamide
• Example 21 Compound 11311, 4-acetyl-N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(3-fluorophenyl)piperazine-1-sulfonamide
• Example 22 Compound 11312, N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(3-fluorophenyl)-4-methylpiperazine-1-sulfonamide
• Example 23 Compound 11313, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(3-fluorophenyl)piperazine-1-sulfonamide hydrochloride
• reaction mixture was cooled down to the room temperature to terminate the reaction. Then, saturated aqueous sodium bicarbonate solution was added to the concentrate, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO 4 , filtered, and concentrated in vacuo.
• Example 24 Compound 11314, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(3-fluorophenyl)-4-(methylsulfonyl)piperazine-1-sulfonamide
• Example 25 Compound 11315, 4-acetyl-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(3-fluorophenyl)piperazine-1-sulfonamide
• Example 26 Compound 11316, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(3-fluorophenyl)-4-methylpiperazine-1-sulfonamide
• Example 27 Compound 11317, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(pyridin-3-yl)piperazine-1-sulfonamide dihydrochloride
• Example 28 Compound 11318, 4-acetyl-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-N-(pyridin-3-yl)piperazine-1-sulfonamide
• Example 29 Compound 11319, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-4-(methylsulfonyl)-N-(pyridin-3-yl)piperazine-1-sulfonamide
• Example 30 Compound 11320, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-4-methyl-N-(pyridin-3-yl)piperazine-1-sulfonamide
• Example 31 Compound 11321, N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(pyridin-3-yl)piperazine-1-sulfonamide dihydrochloride
• Example 32 Compound 11322, 4-acetyl-N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-(pyridin-3-yl)piperazine-1-sulfonamide
• Example 33 Compound 11363, N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-4-methyl-N-phenylpiperazine-1-sulfonamide
• Example 34 Compound 11379, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)-2-fluorobenzyl)-4-(oxetan-3-yl)-N-phenylpiperazine-1-sulfonamide
• Example 35 Compound 11440, N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-phenylthiomorpholine-4-sulfonamide 1,1-dioxide
• N-phenylthiomorpholine-4-sulfonamide 1,1-dioxide 0.220 g, 0.758 mmol
• N,N-dimethylformide 10 mL
• sodium hydride 60.00 %, 0.036 g, 0.909 mmol
• the reaction mixture was treated with methyl 6-(bromomethyl)nicotinate (0.227 g, 0.985 mmol), and stirred for additional 3 hr at the same temperature.
• saturated aqueous sodium bicarbonate solution was added to the reaction mixture, followed by extraction with ethyl acetate.
• Example 36 Compound 11498, N-(3-chloro-4-fluorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)thiomorpholine-4-sulfonamide 1,1-dioxide
• N-(3-chloro-4-fluorophenyl)thiomorpholine-4-sulfonamide 1,1-dioxide (0.400 g, 1.167 mmol) in N,N-dimethylformide (10 mL) was added sodium hydride (60.00 %, 0.061 g, 1.517 mmol) at the room temperature, and the mixture was stirred at the same temperature for 5 min.
• the reaction mixture was treated with methyl 6-(bromomethyl)nicotinate (0.322 g, 1.400 mmol), and stirred for additional 3 hr at the same temperature. Then, saturated aqueous ammonium chloride solution was added to the reaction mixture, followed by extraction with ethyl acetate.
• reaction mixture was cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO 4 , filtered, and concentrated in vacuo.
• Example 37 Compound 11527, N-(2-fluoro-4-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-4-(oxetan-3-yl)-N-phenylpiperazine-1-sulfonamide
• Example 38 Compound 11528, 4-(oxetan-3-yl)-N-phenyl-N-((5-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)piperazine-1-sulfonamide
• Example 39 Compound 11574, N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-4-(oxetan-3-yl)-N-phenylpiperazine-1-sulfonamide
• Example 40 Compound 11575, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-4-(oxetan-3-yl)-N-phenylpiperazine-1-sulfonamide
• Example 41 Compound 11640, (3S,5R)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-4-ethyl-3,5-dimethyl-N-phenylpiperazine-1-sulfonamide
• Example 42 Compound 11641, (3S,5R)-4-acetyl-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-3,5-dimethyl-N-phenylpiperazine-1-sulfonamide
• Example 43 Compound 11642, (3S,5R)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-3,5-dimethyl-N-phenyl-4-propylpiperazine-1-sulfonamide
• Example 44 Compound 11643, (3S,5R)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-3,4,5-trimethyl-N-phenylpiperazine-1-sulfonamide
• Example 45 Compound 11644, (3S,5R)-4-(2,2-difluoroacetyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-3,5-dimethyl-N-phenylpiperazine-1-sulfonamide
• Example 46 Compound 11651, N-(3-chloro-4-fluorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-4-isopropylpiperazine-1-sulfonamide
• Example 47 Compound 11652, N-(3-chloro-4-fluorophenyl)-4-cyclobutyl-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)piperazine-1-sulfonamide
• Example 48 Compound 11653, N-(3-chloro-4-fluorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-4-(oxetan-3-yl)piperazine-1-sulfonamide
• Example 49 Compound 11654, N-(3-chloro-4-fluorophenyl)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-4-methylpiperazine-1-sulfonamide
• Example 50 Compound 11659, (3S,5R)-4-acetyl-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-3,5-dimethyl-N-phenylpiperazine-1-sulfonamide
• Example 51 Compound 11660, (3S,5R)-4-acetyl-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-3,5-dimethyl-N-(pyridin-3-yl)piperazine-1-sulfonamide
• Example 52 Compound 11661, (3S,5R)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-4-ethyl-3,5-dimethyl-N-phenylpiperazine-1-sulfonamide
• Example 53 Compound 11662, (3S,5R)-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-3,4,5-trimethyl-N-(pyridin-3-yl)piperazine-1-sulfonamide
• Example 54 Compound 11670, N-(3-chloro-4-fluorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-4-isopropylpiperazine-1-sulfonamide
• Example 55 Compound 11671, N-(3-chloro-4-fluorophenyl)-4-cyclobutyl-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)piperazine-1-sulfonamide
• Example 56 Compound 11672, N-(3-chloro-4-fluorophenyl)-N-((5-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-4-(oxetan-3-yl)piperazine-1-sulfonamide
• Example 57 Compound 11673, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-4-isopropyl-N-phenylpiperazine-1-sulfonamide
• Example 58 Compound 11674, 4-cyclobutyl-N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenylpiperazine-1-sulfonamide
• Example 59 Compound 11702, 2-((4-(((N-methyl-N-(2-(4-methylpiperazin-1-yl)ethyl)sulfamoyl)(phenyl)amino)methyl))phenyl)-5-(difluoromethyl)-1,3,4-oxadiazole
• Example 60 Compound 11704, 2-((4-(((N-methyl-N-(2-(4-(oxetan-3-yl)piperazin-1-yl)ethyl)sulfamoyl)(phenyl)amino)methyl))phenyl)-5-(difluoromethyl)-1,3,4-oxadiazole
• Example 61 Compound 11713, 2-((4-(((N-methyl-N-(2-(4-acetylpiperazin-1-yl)ethyl)sulfamoyl)(phenyl)amino)methyl))phenyl)-5-(difluoromethyl)-1,3,4-oxadiazole
• Example 62 Compound 11714, 2-((4-(((N-methyl-N-(2-(4-(methylsulfonyl)piperazin-1-yl)ethyl)sulfamoyl)(phenyl)amino)methyl))phenyl)-5-(difluoromethyl)-1,3,4-oxadiazole
• Example 63 Compound 11787, N-(4-(5-(difluoromethyl)-1,3,4-oxadiazol-2-yl)benzyl)-N-phenyl-2,7-diazaspiro[3.5]nonane-7-sulfonamide hydrochloride

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Diabetes (AREA)
• Epidemiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Neurosurgery (AREA)
• Dermatology (AREA)
• Cardiology (AREA)
• Neurology (AREA)
• Biomedical Technology (AREA)
• Hematology (AREA)
• Obesity (AREA)
• Pulmonology (AREA)
• Endocrinology (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Physical Education & Sports Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
• Plural Heterocyclic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)

Priority Applications (17)

Applications Claiming Priority (2)

Publications (1)

Family

ID=57885712

Family Applications (1)

Country Status (21)

Cited By (23)

Families Citing this family (5)

Citations (2)

Family Cites Families (50)

• 2016
  • 2016-07-27 KR KR1020160095326A patent/KR101799005B1/ko active Active
  • 2016-07-27 RU RU2018106904A patent/RU2695227C9/ru active
  • 2016-07-27 CA CA2987570A patent/CA2987570C/en active Active
  • 2016-07-27 MX MX2017017090A patent/MX376585B/es active IP Right Grant
  • 2016-07-27 DK DK16830838.5T patent/DK3328844T3/da active
  • 2016-07-27 BR BR112017027798-0A patent/BR112017027798B1/pt active IP Right Grant
  • 2016-07-27 EP EP16830838.5A patent/EP3328844B1/en active Active
  • 2016-07-27 HU HUE16830838A patent/HUE048534T2/hu unknown
  • 2016-07-27 NZ NZ736432A patent/NZ736432A/en unknown
  • 2016-07-27 PT PT168308385T patent/PT3328844T/pt unknown
  • 2016-07-27 US US15/747,850 patent/US10464911B2/en active Active
  • 2016-07-27 MY MYPI2017703935A patent/MY194018A/en unknown
  • 2016-07-27 WO PCT/KR2016/008218 patent/WO2017018805A1/en not_active Ceased
  • 2016-07-27 TW TW105123853A patent/TWI694074B/zh active
  • 2016-07-27 PL PL16830838T patent/PL3328844T3/pl unknown
  • 2016-07-27 CN CN201680025249.5A patent/CN107980040B/zh active Active
  • 2016-07-27 JP JP2018504096A patent/JP6538266B2/ja active Active
  • 2016-07-27 HR HRP20200280TT patent/HRP20200280T1/hr unknown
  • 2016-07-27 AU AU2016299486A patent/AU2016299486B2/en active Active
  • 2016-07-27 ES ES16830838T patent/ES2774510T3/es active Active
• 2017
  • 2017-10-24 PH PH12017501939A patent/PH12017501939A1/en unknown

Patent Citations (2)

Non-Patent Citations (23)

Also Published As

Similar Documents

Legal Events